Key Takeaways
- A small 2025 randomized trial found low-dose semaglutide reduced drinks per drinking day, heavy drinking days, and craving over nine weeks, but it was a preliminary phase 2 study.
- An earlier 26-week exenatide trial found no overall reduction in heavy drinking days, with a possible benefit only in an exploratory subgroup of participants with obesity.
- A large Swedish registry study linked semaglutide use with fewer alcohol-related hospitalizations, but observational data cannot prove the drug caused the difference.
- GLP-1 drugs are not approved for alcohol use disorder, while naltrexone, acamprosate, and disulfiram are FDA approved and often worth asking about first.
- Reduced craving is not the same as recovery; assessment, evidence-based therapy, and ongoing support remain the foundation of treatment for alcohol use disorder.
If you take Ozempic, Wegovy, Mounjaro, or Zepbound, or know someone who does, you may have heard a version of the same story: the drink that used to sound good at 6 p.m. just stopped calling. That has made GLP-1 and alcohol cravings one of the most talked-about topics in addiction medicine. The interest is real, and so is some early science. But the research is younger and narrower than the headlines suggest, and none of these drugs is approved to treat drinking.
This article walks through what the studies actually found, where they fall short, and what that means if you are worried about your own drinking right now. It is educational, not a treatment recommendation. Whether any medication is right for you is a conversation for you and a prescriber who knows your full history.
GLP-1 medications, defined: drugs that mimic glucagon-like peptide-1, a gut hormone involved in blood sugar, appetite, and fullness. Semaglutide (Ozempic, Wegovy) and liraglutide act on the GLP-1 receptor; tirzepatide (Mounjaro, Zepbound) acts on both the GLP-1 and GIP receptors. In the United States they are approved for type 2 diabetes, weight management, and certain related conditions, not for alcohol use disorder.
Why Researchers Think GLP-1 Drugs Might Affect Drinking
GLP-1 receptors are not only in the gut and pancreas. They also sit in brain regions involved in reward and motivation. Animal studies over many years suggested that activating those receptors can dampen the rewarding pull of alcohol. In one human brain imaging study connected to a Danish trial of the older GLP-1 drug exenatide, participants on the medication showed reduced reactivity to alcohol cues in reward areas such as the ventral striatum.
A plausible mechanism is still not proof that a medication works as a treatment. That is where human trials come in.
What the Research on GLP-1 and Alcohol Cravings Shows So Far
The evidence comes from small randomized trials, large observational studies of health records, and animal research. Each answers a different question.
The evidence so far
Key studies on GLP-1 drugs and drinking
A short history of the most cited research, in the order it was published.
2022
A 26-week Danish trial of exenatide in 127 adults with alcohol use disorder found no overall reduction in heavy drinking days compared with placebo. An exploratory look at participants with obesity suggested a benefit.
Late 2024
A Swedish registry study of about 228,000 people with alcohol use disorder linked periods of semaglutide use with a 36 percent lower risk of alcohol-related hospitalization. Observational, not a trial.
2025
A 9-week randomized trial of low-dose semaglutide in 48 adults found fewer drinks on drinking days, fewer heavy drinking days, and lower craving than placebo.
2026
Rodent research found tirzepatide reduced alcohol intake and relapse-like drinking. Human trials of tirzepatide for alcohol use disorder are registered but not yet reported.
Summary of published studies for educational purposes. Small, short, or observational studies can point in a direction but cannot establish that a drug is a safe and effective treatment for alcohol use disorder.
The 2025 semaglutide trial, published in JAMA Psychiatry, is the result most people are referring to. It was carefully designed and the findings are encouraging: on the days people drank, they drank less, and they reported lower craving. Interestingly, the medication had little effect on how many days people drank at all. The researchers themselves described it as a small, preliminary phase 2 study meant to justify larger trials.
The Honest Limits of the Research
Here is what the current evidence cannot yet tell us.
- The trials are small and short. Forty-eight people over nine weeks is a starting point, not a verdict.
- The participants were not the people most at risk. The semaglutide trial enrolled adults with mostly moderate symptoms who were not seeking treatment. People with severe alcohol use disorder, liver disease, or a history of complicated withdrawal were not the focus.
- Observational studies cannot prove cause. The Swedish registry findings are striking, but people who start a GLP-1 drug may differ in many ways from people who do not. The authors themselves called for clinical trials to confirm the results.
- Body weight may matter. In the exenatide trial, the possible benefit appeared in participants with obesity, while leaner participants did not benefit and may have drunk more. That finding was exploratory, but it is a reason for caution.
- Tirzepatide has almost no human data on drinking yet. Its alcohol research is so far in animals.
| Question | Current answer |
|---|---|
| Are GLP-1 drugs approved to treat alcohol use disorder? | No. They are approved for diabetes and weight management. |
| Is there any randomized evidence they reduce drinking? | Yes, early and limited, mainly one small semaglutide trial. |
| Are there approved medications for alcohol use disorder? | Yes. Naltrexone, acamprosate, and disulfiram are FDA approved. |
| Do we know who would benefit most? | Not yet. Larger, longer trials are needed. |
Confidential Substance Use Help
Wondering whether your drinking needs more than a new prescription?
A confidential assessment can sort out what kind of help actually fits.
Should I Ask My Doctor About Ozempic for Drinking?
You can certainly mention it, and if you already take a GLP-1 drug and notice you are drinking less, tell your prescriber. What we would gently push back on is the idea that a weekly injection is a stand-in for treatment. A few points worth knowing before that conversation:
- Medications with real track records for alcohol use disorder already exist. The National Institute on Alcohol Abuse and Alcoholism lists naltrexone, acamprosate, and disulfiram as FDA approved, and notes that none of them is addictive. They are underused, and they are often worth asking about first.
- GLP-1 drugs have their own side effects, most commonly gastrointestinal ones such as nausea, and they are not appropriate for everyone. Using them outside their approved purpose is a medical decision, not a wellness experiment.
- Reduced craving is not the same as recovery. Many people drink to manage anxiety, sleep, grief, or trauma. If the medication quiets the urge but the reason underneath goes untreated, it tends to find another outlet.
If you are not sure whether your drinking is a problem at all, our piece on gray area drinking is a good place to start.
Where Treatment for Alcohol Use Disorder Stands Today
The most reliable path is still a combination: an honest assessment, evidence-based therapy, approved medication when it fits, and support that lasts beyond the first few weeks. Our overview of alcohol use disorder treatment covers those options in more depth.
At Heights Behavioral Health, outpatient care for drinking starts with a clinical assessment that looks at your drinking, your health, and what else is going on, including anxiety, depression, or trauma that often travels with it. From there, care may include individual and group therapy, a partial hospitalization or intensive outpatient program, evening IOP for people who work, and medication-assisted treatment with naltrexone where appropriate. If you already take a GLP-1 drug, we coordinate with the physician who prescribes it rather than working around them. You can read more about our substance use treatment in Houston.
Crisis notice. Heights Behavioral Health provides scheduled outpatient care and is not an emergency or detox service. If you drink heavily every day, do not stop suddenly without medical advice, because alcohol withdrawal can be dangerous. If you have a seizure, confusion, or hallucinations while withdrawing, call 911. If you are in crisis or thinking about suicide, call or text 988.
Frequently Asked Questions
Does Ozempic reduce alcohol cravings?
Early evidence suggests semaglutide, the drug in Ozempic and Wegovy, may reduce craving and the amount people drink. The best study so far was small and lasted nine weeks, so the effect is promising but not established, and the drug is not approved for alcohol use disorder.
What about Mounjaro or Zepbound and drinking?
Tirzepatide, the drug in Mounjaro and Zepbound, has reduced alcohol intake in animal studies. Human trials for alcohol use disorder are registered, but results are not yet published, so there is very little human evidence.
Are there approved medications for alcohol use disorder?
Yes. Naltrexone, acamprosate, and disulfiram are approved by the FDA for alcohol use disorder. They work best as part of a broader plan that includes therapy and support.
Can I get a GLP-1 drug at Heights for drinking?
No. We do not prescribe GLP-1 drugs for alcohol use. We provide assessment, therapy, outpatient programs, and medication-assisted treatment with naltrexone or buprenorphine where appropriate, and we coordinate with any outside physician who prescribes a GLP-1 drug.
Sources
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025. jamanetwork.com
- Klausen MK, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 2022. insight.jci.org
- Lähteenvuo M, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry, 2025. jamanetwork.com
- EBioMedicine. Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. 2026. pubmed.ncbi.nlm.nih.gov
- National Institute on Alcohol Abuse and Alcoholism (NIAAA). Understanding Alcohol Use Disorder. niaaa.nih.gov
Written and Reviewed by Licensed Clinicians
Joni Ogle is a Licensed Clinical Social Worker (LCSW) and Certified Sex Addiction Therapist (CSAT) with over 37 years of clinical experience in mental health and addiction recovery, dual diagnosis treatment, behavioral addictions, and family intervention. She is the founder of Heights Behavioral Health and Heights Mentoring in Houston, Texas, where she leads a team of licensed clinicians.
Texas LCSW #37376 · Verify license
Deborah Darnell-Drake, LCSW-S, ACSW, LMFT is the Chief Clinical Officer at Heights Behavioral Health and a clinical reviewer. With more than five decades of experience in mental health and substance use disorder treatment, Deborah specializes in addiction, co-occurring mental health conditions, family dynamics, and behavioral addictions including gambling and technology addiction.
Texas LCSW-S #14508 · LMFT #1125 · Verify license
Start a Confidential Conversation
One confidential message connects you with our admissions team and a clear next step. Prefer to talk now? Call (877) 549-5102.
